BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montandon SA, Jornayvaz FR. Effects of Antidiabetic Drugs on Gut Microbiota Composition. Genes (Basel). 2017;8:250. [PMID: 28973971 DOI: 10.3390/genes8100250] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Wang M. New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes. Drug Des Devel Ther 2021;15:4849-63. [PMID: 34876807 DOI: 10.2147/DDDT.S334325] [Reference Citation Analysis]
2 Farup PG, Lydersen S, Valeur J. Are Nonnutritive Sweeteners Obesogenic? Associations between Diet, Faecal Microbiota, and Short-Chain Fatty Acids in Morbidly Obese Subjects. J Obes 2019;2019:4608315. [PMID: 31662903 DOI: 10.1155/2019/4608315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Liu H, Zhang M, Ma Q, Tian B, Nie C, Chen Z, Li J. Health beneficial effects of resistant starch on diabetes and obesity via regulation of gut microbiota: a review. Food Funct 2020;11:5749-67. [PMID: 32602874 DOI: 10.1039/d0fo00855a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Liu YK, Xu X, Zhou XD. [Potential application of human microbiomes in the diagnosis and treatment of type 2 diabetes mellitus]. Hua Xi Kou Qiang Yi Xue Za Zhi 2019;37:556-62. [PMID: 31721508 DOI: 10.7518/hxkq.2019.05.020] [Reference Citation Analysis]
5 Herat LY, Ward NC, Magno AL, Rakoczy EP, Kiuchi MG, Schlaich MP, Matthews VB. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World J Gastroenterol 2020; 26(23): 3225-3235 [PMID: 32684737 DOI: 10.3748/wjg.v26.i23.3225] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1453-68. [PMID: 32969507 DOI: 10.1111/apt.16096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
7 Yang M, Shi FH, Liu W, Zhang MC, Feng RL, Qian C, Ma J. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model.Front Endocrinol (Lausanne). 2020;11:635. [PMID: 33312157 DOI: 10.3389/fendo.2020.00635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wei B, Wang Y, Xiang S, Jiang Y, Chen R, Hu N. Alterations of gut microbiome in patients with type 2 diabetes mellitus who had undergone cholecystectomy. Am J Physiol Endocrinol Metab 2021;320:E113-21. [PMID: 33166187 DOI: 10.1152/ajpendo.00471.2020] [Reference Citation Analysis]
9 McMurdie PJ, Stoeva MK, Justice N, Nemchek M, Sieber CMK, Tyagi S, Gines J, Skennerton CT, Souza M, Kolterman O, Eid J. Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes. BMC Microbiol 2022;22:19. [PMID: 34996347 DOI: 10.1186/s12866-021-02415-8] [Reference Citation Analysis]
10 Farup PG, Valeur J. Faecal Microbial Markers and Psychobiological Disorders in Subjects with Morbid Obesity. A Cross-Sectional Study. Behav Sci (Basel) 2018;8:E89. [PMID: 30262766 DOI: 10.3390/bs8100089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, Yuan Q, Yu H, Xu W, Xie X. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 2019;20:247-60. [PMID: 30384259 DOI: 10.1016/j.redox.2018.09.025] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 32.0] [Reference Citation Analysis]
12 Christodoulou MI, Tchoumtchoua J, Skaltsounis AL, Scorilas A, Halabalaki M. Natural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents? Curr Med Chem. 2019;26:5982-6015. [PMID: 29714135 DOI: 10.2174/0929867325666180430152618] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
13 Zawada A, Rychter AM, Ratajczak AE, Lisiecka-Masian A, Dobrowolska A, Krela-Kaźmierczak I. Does Gut-Microbiome Interaction Protect against Obesity and Obesity-Associated Metabolic Disorders? Microorganisms 2020;9:E18. [PMID: 33374597 DOI: 10.3390/microorganisms9010018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-davis EJ; Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocrine Reviews 2018;39:629-63. [DOI: 10.1210/er.2017-00191] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 15.0] [Reference Citation Analysis]
15 Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med 2019;18:3461-9. [PMID: 31602221 DOI: 10.3892/etm.2019.7943] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
16 Kihl P, Krych L, Buschard K, Wesley JD, Kot W, Hansen AK, Nielsen DS, von Herrath MG. Oral insulin does not alter gut microbiota composition of NOD mice. Diabetes Metab Res Rev 2018;34:e3010. [PMID: 29637693 DOI: 10.1002/dmrr.3010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Liaqat I, Ali NM, Arshad N, Sajjad S, Rashid F, Hanif U, Ara C, Ulfat M, Andleeb S, Awan UF, Bibi A, Mubin M, Ali S, Tahir HM, Ul-Haq I. Gut dysbiosis, inflammation and type 2 diabetes in mice using synthetic gut microbiota from diabetic humans. Braz J Biol 2021;83:e242818. [PMID: 34378656 DOI: 10.1590/1519-6984.242818] [Reference Citation Analysis]
18 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yixia Y, Sripetchwandee J, Chattipakorn N, Chattipakorn SC. The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy. Anaerobe 2021;68:102361. [PMID: 33781900 DOI: 10.1016/j.anaerobe.2021.102361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Hegazy WAH, Rajab AAH, Abu Lila AS, Abbas HA. Anti-diabetics and antimicrobials: Harmony of mutual interplay. World J Diabetes 2021; 12(11): 1832-1855 [PMID: 34888011 DOI: 10.4239/wjd.v12.i11.1832] [Reference Citation Analysis]
21 Choi Y, Bose S, Shin NR, Song EJ, Nam YD, Kim H. Lactate-Fortified Puerariae Radix Fermented by Bifidobacterium breve Improved Diet-Induced Metabolic Dysregulation via Alteration of Gut Microbial Communities. Nutrients 2020;12:E276. [PMID: 31973042 DOI: 10.3390/nu12020276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Brønden A, Knop FK. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. J Clin Endocrinol Metab 2020;105:dgz025. [PMID: 31630179 DOI: 10.1210/clinem/dgz025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Farup PG, Aasbrenn M, Valeur J. Separating "good" from "bad" faecal dysbiosis - evidence from two cross-sectional studies. BMC Obes 2018;5:30. [PMID: 30524735 DOI: 10.1186/s40608-018-0207-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
24 Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62. [PMID: 29703207 DOI: 10.1186/s12933-018-0708-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 16.3] [Reference Citation Analysis]
25 Somm E, Montandon SA, Loizides-Mangold U, Gaïa N, Lazarevic V, De Vito C, Perroud E, Bochaton-Piallat ML, Dibner C, Schrenzel J, Jornayvaz FR. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl Res 2021;227:75-88. [PMID: 32711187 DOI: 10.1016/j.trsl.2020.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
26 Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathog 2021;13:50. [PMID: 34362432 DOI: 10.1186/s13099-021-00446-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Ding QY, Tian JX, Li M, Lian FM, Zhao LH, Wei XX, Han L, Zheng YJ, Gao ZZ, Yang HY, Fang XY, Tong XL. Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota. Front Cell Infect Microbiol 2020;10:530160. [PMID: 33194785 DOI: 10.3389/fcimb.2020.530160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Shao J, Liu Y, Wang H, Luo Y, Chen L. An Integrated Fecal Microbiome and Metabolomics in T2DM Rats Reveal Antidiabetes Effects from Host-Microbial Metabolic Axis of EtOAc Extract from Sophora flavescens. Oxid Med Cell Longev 2020;2020:1805418. [PMID: 32566075 DOI: 10.1155/2020/1805418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tiderencel KA, Hutcheon DA, Ziegler J. Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials. Diabetes Metab Res Rev 2020;36:e3213. [PMID: 31465625 DOI: 10.1002/dmrr.3213] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
30 Gupta S, Sen U. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Pharmacol Res 2019;147:104391. [PMID: 31401210 DOI: 10.1016/j.phrs.2019.104391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
31 Onal EM, Afsar B, Covic A, Vaziri ND, Kanbay M. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. Hypertens Res 2019;42:123-40. [PMID: 30504819 DOI: 10.1038/s41440-018-0144-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
32 Huang PJ, Wei JC, Liu YT, Lin CH, Lin CC, Chen HH. Association between α-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study. Int J Clin Pract 2021;75:e14819. [PMID: 34490702 DOI: 10.1111/ijcp.14819] [Reference Citation Analysis]
33 Lorenzo O, Crespo-Yanguas M, Hang T, Lumpuy-Castillo J, Hernández AM, Llavero C, García-Alonso M, Ruiz-Tovar J. Addition of Probiotics to Anti-Obesity Therapy by Percutaneous Electrical Stimulation of Dermatome T6. A Pilot Study. Int J Environ Res Public Health 2020;17:E7239. [PMID: 33023060 DOI: 10.3390/ijerph17197239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
34 Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, Liberti EA, Saad M, Carvalho C. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem 2018;62:143-54. [PMID: 30292107 DOI: 10.1016/j.jnutbio.2018.07.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
35 Gowd V, Xie L, Zheng X, Chen W. Dietary fibers as emerging nutritional factors against diabetes: focus on the involvement of gut microbiota. Crit Rev Biotechnol. 2019;39:524-540. [PMID: 30810398 DOI: 10.1080/07388551.2019.1576025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
36 Sircana A, Framarin L, Leone N, Berrutti M, Castellino F, Parente R, De Michieli F, Paschetta E, Musso G. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? Curr Diab Rep. 2018;18:98. [PMID: 30215149 DOI: 10.1007/s11892-018-1057-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
37 Merkevičius K, Kundelis R, Maleckas A, Veličkienė D. Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review. Medicina (Kaunas) 2021;57:1084. [PMID: 34684121 DOI: 10.3390/medicina57101084] [Reference Citation Analysis]
38 Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, Arcambal A, Kiuchi MG, Head GA, Schlaich MP, Matthews VB. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection. JACC Basic Transl Sci. 2020;5:169-179. [PMID: 32140623 DOI: 10.1016/j.jacbts.2019.11.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 21.0] [Reference Citation Analysis]
39 Cao TTB, Wu KC, Hsu JL, Chang CS, Chou C, Lin CY, Liao YM, Lin PC, Yang LY, Lin HW. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies. Front Endocrinol (Lausanne) 2020;11:573891. [PMID: 33071980 DOI: 10.3389/fendo.2020.573891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
40 Radbakhsh S, Atkin SL, Simental-Mendia LE, Sahebkar A. The role of incretins and incretin-based drugs in autoimmune diseases. Int Immunopharmacol 2021;98:107845. [PMID: 34126341 DOI: 10.1016/j.intimp.2021.107845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Lee SE, Choi Y, Jun JE, Lee YB, Jin SM, Hur KY, Ko GP, Lee MK. Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial. Diabetes Metab J 2019;43:422-31. [PMID: 31237126 DOI: 10.4093/dmj.2018.0090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Ahmed LA, Salem MB, Seif El-Din SH, El-Lakkany NM, Ahmed HO, Nasr SM, Hammam OA, Botros SS, Saleh S. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways. Eur J Pharmacol 2020;887:173461. [PMID: 32758573 DOI: 10.1016/j.ejphar.2020.173461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 Umirah F, Neoh CF, Ramasamy K, Lim SM. Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: A systematic review. Diabetes Res Clin Pract 2021;173:108689. [PMID: 33549678 DOI: 10.1016/j.diabres.2021.108689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Rahayu ES, Utami T, Mariyatun M, Hasan PN, Kamil RZ, Setyawan RH, Pamungkaningtyas FH, Harahap IA, Wiryohanjoyo DV, Pramesi PC, Cahyanto MN, Sujaya IN, Juffrie M. Gut microbiota profile in healthy Indonesians. World J Gastroenterol 2019; 25(12): 1478-1491 [PMID: 30948911 DOI: 10.3748/wjg.v25.i12.1478] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10(3): 154-168 [PMID: 30891151 DOI: 10.4239/wjd.v10.i3.154] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
46 Zhang M, Feng R, Yang M, Qian C, Wang Z, Liu W, Ma J. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care 2019;7:e000717. [PMID: 31641523 DOI: 10.1136/bmjdrc-2019-000717] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
47 Chai Y, Luo J, Bao Y. Effects of Polygonatum sibiricum saponin on hyperglycemia, gut microbiota composition and metabolic profiles in type 2 diabetes mice. Biomed Pharmacother 2021;143:112155. [PMID: 34517283 DOI: 10.1016/j.biopha.2021.112155] [Reference Citation Analysis]